Blau Farmaceutica SA
(BSP:BLAU3)
R$
9.68
+0.18 (+1.89%)
Market Cap: 2.24 Bil
Enterprise Value: 2.19 Bil
PE Ratio: 7.52
PB Ratio: 0.96
GF Score: 84/100 
Q2 2026 Blau Farmaceutica SA Earnings Call Transcript
Aug 12, 2026 / 02:00PM GMT
Release Date Price:
R$9.3
(+11.38%)
Key Points
Positve
- Blau Farmaceutica SA (BSP:BLAU3) reported a 10% net revenue growth in the first half of 2026, in line with its three-year average, and expects growth to accelerate in the second half with new production lines and a more favorable comparison basis.
- The company achieved a significant improvement in profitability, with gross margin and recurring EBITDA margin both expanding, including a sequential improvement from Q1 to Q2, reaching a recurring EBITDA margin of 25%.
- Blau Farmaceutica SA (BSP:BLAU3) generated strong cash flow, with operating cash generation 2.4 times higher in the semester, representing about 92% of recurring EBITDA, and free cash flow of $70 million after CapEx.
- The company maintained a net cash position, with cash exceeding debt, and improved this by 49 million reais in the quarter, supported by disciplined capital allocation and lower CapEx relative to EBITDA.
- Blau Farmaceutica SA (BSP:BLAU3) is advancing its strategic pipeline, including the launch of its first 100% Brazilian-produced monoclonal antibody (pembrolizumab), which is expected to boost growth and margins in the medium term.
- The company successfully completed the Bergamo turnaround, expanded production capacity to an all-time high, and increased operational efficiency, contributing to improved margins and competitiveness.
- Blau Farmaceutica SA (BSP:BLAU3) is diversifying its customer base and increasing direct sales to hospitals, which has improved sales quality and profitability, with new contracts and partnerships in the private channel.
- The company has a robust pipeline of new launches, with revenue from launches growing over 30% in the last 12 months, and is focusing on higher-value biological products with lower competition.
- Working capital improved sequentially by 300 basis points to 50.8% of revenue, with a third consecutive reduction in inventories, and the company has a clear target to further reduce inventory days to 180.
- Blau Farmaceutica SA (BSP:BLAU3) is expanding its geographic presence, operating in nine countries and exporting to over 20 markets, and has increased its addressable market in Brazil by approximately 1.5 billion reais.
Negative
- Blau Farmaceutica SA (BSP:BLAU3) faced challenges in the public channel due to phasing of deliveries, leading to lower growth in Q2 compared to Q1, and the company noted a more challenging comparison basis.
- The private market was impacted by high interest rates and a difficult macro environment, which pressured growth, although there was an acceleration from Q1 to Q2.
- The company's recurring net income was negatively impacted by exchange rate variations, with growth of only 12% in the semester, compared to 18% excluding the effect.
- Blau Farmaceutica SA (BSP:BLAU3) is experiencing delays in obtaining authorization from local health inspection authorities for new production lines, which has postponed the launch of products and limited revenue growth.
- The company had to anticipate receivables of 50 million reais in Q2, reflecting a strategic decision to accommodate customer needs, but this indicates ongoing credit risk and market challenges.
- Working capital remains a priority, with inventory levels still high, and the company acknowledges the need for further improvement to reach its target of 180 days, which depends on new line approvals.
- The company is unable to execute share buybacks due to a free float waiver, and management believes shares are undervalued, but they cannot take action at current levels.
- Blau Farmaceutica SA (BSP:BLAU3) faces a competitive environment in the generic hospital market, with many players and more capacity than demand, requiring careful management of pricing and credit.
- The company has a provision related to an M&A acquisition (Blau Goyas) that is under legal dispute, which could result in a non-recurring charge, though management believes it may be reversed.
- CapEx is expected to accelerate in the second half of 2026, particularly for the biological plant and Pernambuco construction, which could pressure cash generation, though it remains below EBITDA.
Matheus Fujisawa
Blau Farmaceutica SA - Investor Relations
Good morning, everyone. Welcome to the earnings call for the second quarter of 2026 at Blau Pharmaceutical. We're live at Blau Studios in Sao Paulo with Marcelo Hahn, CEO and Founder; Douglas Rodrigues, CFO and Investor Relations Director; and me, Matheus Fujisawa, Investor Relations Our call is being held in Portuguese with some attention translation into English and will be available timely on the company's IR website.
Just to show you the agenda today, we'll start off with Marcelo presenting the highlights. Then I will come back and we'll talk about the pipeline and revenue. Then Douglas will talk about the operational financial aspects and Marcelo gets back for the final comments. At the end of our presentation, we'll have our Q&A section. With a priority of course for sell side analysts. Analysts who want to ask questions should click the raise hand on Zoom and that's located at the bottom part of the screen. Other investors can send their questions through the chat.
Now, I would like to pass the floor on to Marcelo
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers